US Patent

US12311027 — Pharmaceutical compositions having improved storage stability

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2033-09-19 · 7y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition with improved storage stability for a hydrolytically labile antipsychotic agent.

USPTO Abstract

The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.

Drugs covered by this patent

Aristada (ARIPIPRAZOLE LAUROXIL) · Alkermes Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-543`	—	Aristada
`U-543`	—	Aristada
`U-543`	—	Aristada
`U-543`	—	Aristada

Patent Metadata

Patent number: US12311027
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Alkermes Pharma Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.